Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal (June 26, 2025) by Annalee Armstrong. Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic mitochondria. Minovia Therapeutics, an Israeli biotech hoping to get to the root causes of disease and aging, is planting itself onto the Nasdaq through a special purpose acquisition
Summary – Ross has developed proprietary technology to mine microbiomes, already discovering 110,000+ novel small molecules with potential applications across pharmaceuticals, agriculture, and beyond.
Why investors should tune in:
– First-mover advantage in an untapped market
– Technology validated by Los Alamos National Lab
– Platform business model with multiple revenue streams
– Potential to generate 4X the human knowledge on microbial molecules annually
Ross brings exceptional credentials as a serial entrepreneur who’s built Inc. 500 companies and secured backing from DARPA, NIH, and major research institutions.
Summary – Join us for an inspiring episode of Mastering the Numbers as host Joe Mallo sits down with Ross Youngs, the visionary founder and CEO of Biosortia. In this in-depth conversation, Ross shares his journey of groundbreaking innovation, from his early days in plastics manufacturing to revolutionizing drug discovery. Learn how Biosortia is leveraging advanced technology and natural resources to access molecules that could transform medicine, agriculture, and cosmetics. Ross also dives into the challenges of scaling a startup, the importance of partnerships, and how perseverance led to game-changing advancements in their mission to serve the world’s most critical needs. Discover how Biosortia is breaking barriers by unlocking 100% of nature’s molecular secrets, a feat supported by top institutions like DARPA, ARPA-E, and Los Alamos National Lab. Ross discusses the potential of their technology to reduce pharmaceutical costs, foster global health innovation, and fuel competition in critical markets. This is a must-watch for entrepreneurs, scientists, and anyone curious about the future of biotechnology.
